Navigation Links
Nativis Announces Name Change To EMulate Therapeutics, Inc.

Nativis, Inc., today announced the Company has changed its name to EMulate Therapeutics, Inc. The name change is effective immediately for the clinical stage, therapeutic device company, which is developing non-invasive treatments for cancers and other serious diseases.

In making the announcement, Chris Rivera, Chief Executive Officer, said, “the renaming of the company to EMulate Therapeutics, Inc. more clearly represents and describes the technology being used to treat cancers and other serious diseases by using the recorded magnetic signature of a chemical, biochemical or biological agent to “emulate” the effects of that agent using the company’s ultra-low radio frequency energy (ulRFE®) system.” The ulRFE signal is created by measuring and recording the oscillating magnetic field produced by drugs or other molecules in solution. The signal is then used to reproduce the recorded magnetic field using an electromagnetic coil worn by the patient externally.

EMulate Therapeutics’ ulRFE system is currently in clinical trials in patients diagnosed with glioblastoma (GBM). The company is also preparing a Humanitarian Device Exception (HDE) application for the treatment of pediatric patients diagnosed with diffuse midline glioma (including diffuse intrinsic pontine glioma) and an application to secure regulatory approval for treatment of GBM in the European Union and other markets.

In further news, EMulate Therapeutics announced the selection of a clinical research organization (CRO) to conduct pivotal clinical studies for the Voyager system for the treatment of GBM. In making this announcement, Rivera revealed that CurAccel, LLC of Newtown, PA, has been selected to conduct a large, global pivotal study in patients with newly diagnosed GBM.

“We are excited to have an agile and entrepreneurial CRO partnering with EMulate Therapeutics on this critically important pivotal study,” stated Rivera. “The data in previously conducted feasibility studies show the EMulate Therapeutics Voyager device is safe for the treatment of GBM, with encouraging clinical response. We are now moving on to the all-important pivotal clinical studies as a precursor to a marketing authorization application to FDA for treatment of adults with GBM.

“CurAccel is grateful for this opportunity to play a part in the success of EMulate Therapeutics’ clinical development to deliver novel treatment to benefit GBM patients and their families,” commented Roberta Sapone, CurAccel’s Director of Business Development. “We look forward to propelling this partnership to support the goal of EMulate Therapeutics to bring this innovative treatment to market.”

The new EMulate Therapeutics web site can be viewed at

About EMulate Therapeutics
Founded in 2002 and headquartered in Seattle, WA, EMulate Therapeutics is a clinical-stage therapeutic device company. EMulate Therapeutics has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via simple-to-use non-invasive devices called EMulate Therapeutics Voyager system. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of medical conditions, as well as to veterinary medicine and non-medical applications. EMulate Therapeutics’ initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies, which often results in poor outcomes and devastating side effects. Additional pre-clinical work is focused on exploring new applications in other oncology settings and pain management. The EMulate Therapeutics Voyager system is an investigational medical device, limited by United States law to investigational use only.

About CurAccel
CurAccel is a full-service global contract research organization (CRO) of outsourced early and late phase services for drug and device development that caters to small and mid-sized pharmaceutical, biotechnology, and medical device industries. CurAccel’s vision, “to become the industry leader in driving the science to standard of care,” truly exemplifies the focus and reason for our partnership with our clients.

Media Contact:
Dennis Kroft

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology news :

1. Nativis Announces Publication of Study in Patients with Recurrent Glioblastoma (rGBM)
2. Merck Animal Health announces Vetsulin
3. AAPS announces 2013 National Biotechnology Conference award winners
4. PLOS announces Accelerating Science Award Program
5. DFG announces recipients of 2013 Heinz Maier-Leibnitz Prize
6. Missouri Botanical Garden program announces collaboration with LHerboretum
7. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
8. Chiltern Announces The Promotion Of Alecia Barbee To VP, Global Biometrics
9. DigitalPersona Announces U.are.U Software Development Kit (SDK) for Android Applications
10. PatientStream announces the industrys first Multilingual family waiting room board
11. Wiley announces increase in Impact Factors
Post Your Comments:
(Date:4/25/2019)... ... , ... In recent years the neurocognitive effects of treatments ... cases the magnitude of these deficits and the long-term impact on cognitive maturation ... may impact developmental trajectories, and patients are often so unwell at the time ...
(Date:4/25/2019)... ... April 24, 2019 , ... In a letter ... a broad collective of 62 individual scientists, bioethicists, and biotechnology executives, including past-presidents ... Cell Therapy (ASGCT), across industry and academia called for collaboration on a binding ...
(Date:4/25/2019)... CHESTER, Ohio (PRWEB) , ... April 25, 2019 ... ... research agents, as well as screening tools, has strengthened its commitment to meeting ... can be used in any application where inhibition of its targeted proteases is ...
Breaking Biology News(10 mins):
(Date:5/4/2019)... ... May 03, 2019 , ... Diopsys Inc, ... Diopsys® ffERG/Photopic Negative Response vision test, a new full field electroretinography (ffERG) ... estimated that 6.3 million Americans will have glaucoma, with black Americans having the ...
(Date:5/2/2019)... , ... May 02, 2019 , ... Stay on top ... medical device and food industries. Access to all webinars is free, so be sure ... in your field! , Visit to see our upcoming webinars: , ...
(Date:4/25/2019)... ... April 23, 2019 , ... Frank is an albino, deaf Great Dane. His owners rescued ... due to his health issues. Despite his hearing impairment, he was always an active and ... would play all day, every day. As the two grew, playtime became rougher and Frank ...
(Date:4/16/2019)... , ... April 16, 2019 , ... ... Sources and their project partner, the U.S. Army Center for Environmental Health Research ... Biomonitor Through Combined In-Licensing/Out-Licensing.” , Blue Sources, a veteran-owned company located at the ...
Breaking Biology Technology: